By Colin Kellaher
Immunovant unveiled a series of executive changes that more closely aligns the clinical-stage immunology company with majority shareholder Roivant Sciences.
Immunovant on Monday said Pete Salzmann has retired as chief executive and a director of the New York company, and that Eric Venker, a board member who also serves as Roivant's president, has stepped in as CEO.
The company said Salzmann, who joined as CEO in 2019, will be eligible for severance benefits as part of a separation agreement.
Immunovant also said Renee Barnett has stepped down as chief financial officer and has been succeeded by Tiago Girao, who has served as finance chief for multiple Roivant units since 2019.
The company said Barnett, 45 years old, will receive an annual base salary of $481,000 and an annual bonus with a target of 45% of his base pay, adding that it expects to sign a separation agreement with Barnett that includes severance benefits.
Immunovant said the executive changes are part of a broader strategic transition with Roivant that increases the pharmaceutical company's operational involvement and strategic oversight of Immunovant, which was spun out of Roivant in 1999.
Roivant still owns about 57% of Immunovant.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 21, 2025 07:44 ET (11:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.